7498 Results (Page 238 of 300)
Pharmaceuticals Markets Research Reports
Philippines Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030. The Infectious Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Glovax Biotech, United Laboratories and Pharex Health Corporation. The Infectious Disease Therapeutics market in the Philippines is segmented into different therapeutic areas and different diseases type. The major factors affecting the Philippines' infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of the Philippines.
Nigeria Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Nigeria infectious disease therapeutics market will reach a value of $163.7 Mn from $107.9 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030. The Infectious Disease Therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as Fidson Healthcare, Emzor Pharmaceutical and Afrigen Biologics. The Infectious Disease Therapeutics market in Nigeria is segmented into different therapeutic areas and different diseases type. The major factors affecting the Nigeria infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Nigeria.
Mexico Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes Laboratories, BIRMEX and Liomont Laboratories. The Infectious Disease Therapeutics market in Mexico is segmented into different therapeutic areas and different diseases type. The major factors affecting the Mexico infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of Mexico.
Malaysia Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga Berhad, Duopharma Biotech and Kotra Pharma. The Infectious Disease Therapeutics market in Malaysia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Malaysia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Malaysia.
China Alzheimer’s Disease Drugs Market Analysis
The China Alzheimer’s Disease Drugs market was valued at $1.24 Bn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $2.64 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly and Company, H. Lundbeck A/S, Johnson and Johnson, Hengrui Medicine Co, Jiangsu Hengrui, Novartis AG, Chongqing Zhifei Biological Products, Pfizer and CSPC Pharmaceutical Group among others.
Japan Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030. Infectious Disease Therapeutics in Japan is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical. The Infectious Disease Therapeutics market in Japan is segmented into different therapeutic areas and different diseases type. The major factors affecting the Japanese infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Japan.
Italy Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Italy infectious disease therapeutics market will reach a value of $3.89 Bn from $2.88 Bn in 2022, growing at a CAGR of 3.9% during 2022-2030. Infectious Disease Therapeutics in Italy is dominated by a few domestic pharmaceutical companies such as Menarini, Dompé and IRBM. The infectious disease therapeutics market in Italy is segmented into different therapeutic areas and different treatment types. The major factors affecting the Italy infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of Italy.
Africa Alzheimer’s Disease Drugs Market
The Africa Alzheimer’s Disease Drugs market was valued at $231 Mn in 2022 and is estimated to expand at a CAGR of 9.92% from 2022-30 and will reach $493 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Biogen, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, and Pfizer among others.
Indonesia Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Indonesia infectious disease therapeutics market will reach a value of $1011 Mn from $719.22 Mn in 2022, growing at a CAGR of 4.4% during 2022-2030. Infectious Disease Therapeutics in Indonesia is dominated by a few domestic pharmaceutical companies such as Pharos Indonesia, Bio Farma and Kalbe Farma. The Infectious Disease Therapeutics market in Indonesia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Indonesia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Indonesia.
Germany Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the German infectious disease therapeutics market will reach a value of $5.37 Bn from $4.39 Bn in 2022, growing at a CAGR of 2.6% during 2022-2030. Infectious Disease Therapeutics in Germany is dominated by a few domestic pharmaceutical companies such as BioNTech, Evotec and InfectoPharm. The Infectious Disease Therapeutics market in Germany is segmented into different therapeutic areas and different diseases type. The major factors affecting the German infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious disease treatment in various areas of Germany.
Australia Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Australia infectious disease therapeutics market will reach a value of $2.27 Bn from $1.44 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in Australia is dominated by domestic pharmaceutical companies such as AdAlta, Starpharma and CSL. The Infectious Disease Therapeutics market in Australia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Australia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various of areas of Australia.
Brazil Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Brazil infectious disease therapeutics market will reach a value of $4.5 Bn from $3.1 Bn in 2022, growing at a CAGR of 5.4% during 2022-2030. Infectious Disease Therapeutics in Brazil is dominated by a few domestic pharmaceutical companies such as Cristália, Fiocruz and Eurofarma. The Infectious Disease Therapeutics market in Brazil is segmented into different therapeutic areas and different diseases type. The major factors affecting the Brazil infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of Brazil.
China Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the China infectious disease therapeutics market will reach a value of $15.19 Bn from $9.64 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as WuXi Biologics, Fosun Pharma and CanSino Biologics. The infectious disease therapeutics market in China is segmented into different therapeutic areas and different treatment types. The major factors affecting the China infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of China.
Egypt Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Egypt infectious disease therapeutics market will reach a value of $528.93 Mn from $335.64 Mn in 2022, growing at a CAGR of 5.9% during 2022-2030. The Infectious Disease Therapeutics in Egypt is dominated by a few domestic pharmaceutical companies such as EIPICO, Pharco Pharmaceuticals and Memphis Pharmaceutical. The Infectious Disease Therapeutics market in Egypt is segmented into different therapeutic areas and different diseases type. The major factors affecting the Egypt infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various of areas of Egypt.
France Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the France infectious disease therapeutics market will reach a value of $4.29 Bn from $3.3 Bn in 2022, growing at a CAGR of 3.4% during 2022-2030. The Infectious Disease Therapeutics in France is dominated by a few domestic pharmaceutical companies such as BioMérieux, Sanofi and Institut Mérieux. The Infectious Disease Therapeutics market in France is segmented into different therapeutic areas and different diseases type. The major factors affecting the France infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious diseases treatment in various areas of France.
APAC Alzheimer’s Disease Drugs Market
The APAC Alzheimer’s Disease Drugs market was valued at $3.24 Bn in 2022 and is estimated to expand at a CAGR of 9.69% from 2022-30 and will reach $6.79 Bn in 2030. One of the main reasons propelling the growth of this market is government initiatives and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Eisai Co., Daiichi Sankyo Company, Pfizer, Novartis International AG, H Lundbeck A/S, and Merck & Co., among others.
US Oncology Therapeutics Market Analysis
The US oncology therapeutics market is projected to grow from $83 Bn in 2022 to $172 Bn by 2030, registering a CAGR of 9.6% during the forecast period of 2022-30. The development of new and innovative cancer treatments, such as immunotherapies and targeted therapies, is driving the growth of the oncology therapeutics market. This market is highly competitive, with many large pharmaceutical companies and biotech companies competing for market share. Some of the major players in the market include Roche, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, AstraZeneca, and Johnson & Johnson
US Lung Cancer Therapeutics Market Analysis
The US lung cancer therapeutics market is projected to grow from $4 Bn in 2022 to $6.5 Bn by 2030, registering a CAGR of 6.3% during the forecast period of 2022–30. According to the American Cancer Society, lung cancer is the leading cause of cancer deaths in the US for both men and women. In 2022, it is estimated that there will be about 235,760 new cases of lung cancer and 131,880 deaths from the disease in the US. Some of the key players in the US lung cancer therapeutics market include AstraZeneca, Pfizer, Roche, Merck, and Bristol-Myers Squibb, among others.
Brazil Rheumatology Drugs Market Analysis
Brazil's rheumatology drugs market is projected to grow from $1.526 Bn in 2022 to $2.057 Bn by 2030, registering a CAGR of 3.80% during the forecast period of 2022-2030. The prevalence of rheumatic diseases, such as osteoarthritis, rheumatoid arthritis, and lupus, is high in Brazil, which drives the demand for rheumatology drugs. According to a study by the Brazilian Society of Rheumatology, around 30 million Brazilians suffer from some type of rheumatic disease. Aché is one of the largest pharmaceutical companies in Brazil, with a focus on research and development of innovative drugs. The company has a strong presence in the rheumatology drugs market, with products such as Artrinovo and Artril.
Germany Acne Therapeutics Market Analysis
Germany acne therapeutics market is projected to grow from $367 Mn in 2022 to $538 Mn in 2030 with a CAGR of 4.9% for the forecast year 2022-2030. The market is anticipated to grow as most of the German population is becoming aware of acne and its treatment options. The Germany acne therapeutics market is segmented by treatment, route of administration, age group, and distribution channel. Pharall, Oranis, and Teva Pharmaceuticals are some of the key competitors in the market.
Egypt Acne Therapeutics Market Analysis
Egypt's acne therapeutics market is projected to grow from $28 Mn in 2022 to $53 Mn in 2030 with a CAGR of 8.2% for the year 2022-2030. Major market drivers include the growing prevalence of acne and the demand for novel therapeutics such as hormonal therapy for its treatment in Egypt. The Egypt acne therapeutics market is segmented by treatment, route of administration, age group, and by distribution channel. Copad Pharma, Delta Pharma, and Proactiv Company Sàrl are the key players in the market.
Brazil Acne Therapeutics Market Analysis
Brazil's acne therapeutics market is expected to witness growth from $251 Mn in 2022 to $454 Mn in 2030 with a CAGR of 7.7% for the year 2022-2030. The rising prevalence of acne and the demand for innovative treatments for its treatment in Brazil are the major drivers for the growth of the market. The Brazil acne therapeutics market is segmented by treatment, route of administration, age group, and by distribution channel. Some of the key players in the market include Mantecorp Farmasa, EMS Pharma, and Teva Pharmaceuticals.
Italy Acne Therapeutics Market Analysis
The Italy acne therapeutics market is projected to grow from $241 Mn in 2022 to $390 Mn in 2030 with a CAGR of 6.2% for the year 2022-2030. The rise in disposable incomes in Italy and growing skincare concerns are the major factors driving the expansion of the market. The Italy acne therapeutics market is segmented by treatment, route of administration, age group, and distribution channel. Farmabios SpA, AmypoPharma, and Allergan are some of the key players in the market.
Spain Acne Therapeutics Market Analysis
The Spain acne therapeutics market is expected to witness growth from $194 Mn in 2022 to $302 Mn in 2030 with a CAGR of 5.7% for the year 2022-2030. As more and more population becomes aware of the available acne therapies, the market for acne therapeutics is anticipated to expand. The Spain acne therapeutics market is segmented by treatment, route of administration, age group, and distribution channel. TecnyFarma, Farmasierra, and GlaxoSmithKline are some of the key competitors in the market.
UK Acne Therapeutics Market Analysis
As Acne vulgaris continues to affect almost 34% of adults in the UK, the UK acne therapeutics market is expected to grow from $261 Mn in 2022 to $377 Mn in 2030 with a CAGR of 4.7% for the year 2022-2030. Revolutionary acne therapeutics options and acne awareness campaigns in the UK are responsible for the growth of the UK acne therapeutics market. The market is segmented by treatment, route of administration, age group, and by distribution channel. Chugai, Chatfield, and Takeda are some of the key competitors in the UK acne therapeutics market.
